Overview

Adalimumab in Severe and Acute Sciatica

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether adalimumab (a TNF-alpha inhibitor) is effective in the treatment of severe and acute sciatica.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Geneva
Treatments:
Adalimumab